Asiatic health news 08.04.13

546 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
546
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Asiatic health news 08.04.13

  1. 1. April 8, 2013 Asiatic Health News Clinical trial: A randomized controlled cross-over study of Flupenthixol + Melitracen in Functional Dyspepsia. BACKGROUND: Functional dyspepsia is a prevalent condition associated with diminished quality of life (QoL) and high economic burden. AIM: To study the efficacy of a combination of Flupenthixol and Melitracen (F+M) with anxiolytic and antidepressant properties in functional dyspepsia using a randomized controlled cross- over design. 74% 26% Functional Dyspepsia Placbo Antison (Flupenthixol + Melitracen) RESULTS: Twenty-five patients (14 females, 11 males; mean age = 34.3 +/- 9.9 years) were enrolled and 24 completed the 8-week study. There was a significant improvement in subjective global symptom relief with Flupenthixol + Melitracen vs. placebo (ITT: 73.9% vs. 26.1%, P = 0.001). No difference was noted whether the initial treatment was Flupenthixol + Melitracen or placebo. No significant side effects were noted.Ref: 1. Aliment Pharmacol Ther. 2008 Jun 1;27 (11): 1148-55. CONCLUSIONS: A combination of Flupenthixol and Melitracen is safe and effective in the short-term treatment of functional dyspepsia. Flupenthixol + Melitracen is associated with significant improvement in Quality of Life independent of the presence of Anxiety & Depression. ITT=Intent to treat Courtesy By Now available in Alu-Alu Blister Flupentixol BP 0.5 mg + Melitracen INN 10 mg A new dimension for treating Anxiety and Depression

×